| Literature DB >> 28321212 |
Ruobing Wang1, Xuebin Li2, Qi Wang1, Yawei Zhang1, Hui Wang1.
Abstract
The incidence of cardiac implantable electronic device (CIED) infections is rapidly increasing worldwide. However, the microbiological characteristics and clinical features of symptomatic CIED infections are not well described. The present study included patients with CIED infections in China, and their pocket tissues were collected for clinical microbiological determination. A total of 219 patients with CIED infections were investigated; of these patients, 145 (66.2%) were positive for CIED infection in pocket tissue cultures and 24 (11.0%) were positive in both blood and pocket tissue cultures. Patients with recurrent infections and patients with systemic infections tended to have higher rates of positive cultures from pocket tissue. In addition, patients with lung diseases were more likely to have early CIED infections than late CIED infections, while patients with liver diseases were more susceptible to systemic infections than local infections. Staphylococcus species were the most common cause of CIED infections; coagulase-negative staphylococci was the predominant type (accounting for 45.2% in all cases and 68.3% in culture-positive cases). None of the Staphylococcus isolates were resistant to gentamicin, linezolid or vancomycin. Gram-negative bacilli accounted for 9.1% of all cases and 13.8% of culture-positive cases. Significant differences in the distribution of different pathogens were identified between primary infections and recurrent infections, between local infections and systemic infections, and between early infections and late infections. Our data describe the microbiological characteristics and clinical features of CIED infections, and provide evidence for advisory guidelines on the management of CIED infections in China.Entities:
Keywords: Cardiac implantable electronic device (CIED) infection; clinical characteristics; culture; microbial diagnosis; pocket
Year: 2017 PMID: 28321212 PMCID: PMC5337500 DOI: 10.3389/fmicb.2017.00360
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Clinical information and demographics of patients with cardiac implantable electronic device (CIED) infection.
| Demographics | |
| Median age at study (max, min), years | 68 (58-77) |
| Male, | 161 (73.5) |
| Median duration of infection (max, min), days | 23 (10-37) |
| Underlying diseases | |
| Lung diseases, | 23 (10.5) |
| Renal diseases, | 27 (12.3) |
| Liver diseases, | 24 (11.0) |
| Diabetes mellitus, | 53 (24.2) |
| Hypertension, | 106 (48.4) |
| Types of infection | |
| Early post-implantation inflammation, | 32 (14.6) |
| Generator pocket infection, | 152 (69.4) |
| Constitutional symptoms, | 24 (11.0) |
| CIED-LI/IE∗, | 11 (5.0) |
| Positive culture results | |
| Blood, | 24 (11.0) |
| Pocket tissue, | 145 (66.2) |
| Treatment | |
| Re-implantation, | 137 (62.6) |
| Inappropriate empirical antimicrobial therapy | 68 (31.1) |
| Definitive antimicrobial therapy∗∗, | 79 (36.1) |
| Outcome | |
| Median length of stay (max, min), days | 15 (13-20) |
| In-hospital death, | 2 (0.9) |
Comparison of clinical characteristics and outcomes between primary and recurrent CIED infections.
| Characteristics | Primary infection ( | Recurrence ( | |
|---|---|---|---|
| Infection features | |||
| Median duration of infection occurrence after last procedure (max, min), months | 24 (11.35–47) | 16 (6–36) | 0.171 |
| Systemic infection, | 15 (13.4) | 21 (19.6) | 0.213 |
| Positive culture results | |||
| Pocket tissue, | 66 (58.9) | 79 (73.8) | 0.020∗ |
| Blood, | 8 (8.4) | 16 (19.0) | 0.064 |
| Treatment | |||
| Inappropriate empirical antimicrobial therapy, | 35 (32.1) | 33 (31.1) | 0.877 |
| Definitive antimicrobial therapy, | 31 (28.4) | 48 (45.3) | 0.010∗ |
| Outcomes | |||
| Median length of stay (max, min), days | 15 (13–19.75) | 15 (12–20) | 0.916 |
| In-hospital death, | 0 | 2 (1.9) | 0.146 |
Comparison of clinical characteristics and outcomes between early and late CIED infections.
| Characteristics | Early infection (≤6 months) ( | Late infection (>6 months) ( | OR (95%CI) | |
|---|---|---|---|---|
| Underlying diseases | ||||
| Lung diseases, | 10 (20.4) | 14 (8.2) | 0.016 | 2.857 (1.180-6.917) |
| Renal diseases, | 5 (10.2) | 18 (10.6) | 0.938 | |
| Liver diseases, | 4 (8.2) | 23 (13.5) | 0.314 | |
| Diabetes mellitus, | 17 (34.7) | 36 (21.2) | 0.052 | |
| Hypertension, | 25 (51.0) | 81 (47.6) | 0.677 | |
| Positive test results | ||||
| TEE∗, | 4 (8.2) | 7 (4.1) | 0.253 | |
| Blood culture, | 8 (16.3) | 16 (9.4) | 0.107 | |
| Pocket tissue culture, | 35 (71.4) | 110 (64.7) | 0.381 | |
| Outcomes | ||||
| Median length of stay (max, min), days | 15 (12-19) | 15 (13-20) | 0.694 | |
| In-hospital death, | 1 (2.0) | 1 (0.6) | 0.346 | |
Comparison of clinical characteristics, treatment and outcomes between local and systemic CIED infections.
| Characteristics | Local infection ( | Systemic infection ( | OR (95% CI) | |
|---|---|---|---|---|
| Underlying diseases | ||||
| Lung diseases, | 21 (11.5) | 3 (8.3) | 0.581 | |
| Renal diseases, | 24 (13.1) | 3 (8.3) | 0.425 | |
| Liver diseases, | 15 (8.2) | 8 (22.2) | 0.012ˆ* | 3.338 (1.292–8.626) |
| Diabetes mellitus, | 44 (24.0) | 9 (25.0) | 0.903 | |
| Hypertension, | 93 (50.8) | 13 (36.1) | 0.106 | |
| Positive pocket tissue culture, | 114 (62.3) | 31 (86.1) | 0.006ˆ* | |
| Treatment | ||||
| Inappropriate empirical antimicrobial therapy, | 54 (30.2) | 14 (38.9) | 0.305 | |
| Definitive antimicrobial therapy, | 59 (33.0) | 20 (55.6) | 0.010ˆ* | |
| Outcomes | ||||
| Median length of stay (max, min), days | 15 (12-18) | 20.5 (14.25-28) | <0.001ˆ* | |
| In-hospital death, | 2 (1.1) | 0 | 0.529 | |
In vitro activities of antimicrobial agents against Staphylococcus sp..
| Antimicrobial agent | Remaining coagulase-negative staphylococci ( | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R (%) | I (%) | MIC50 | MIC90 | MIC range | R (%) | I (%) | MIC50 | MIC90 | MIC range | R (%) | I (%) | MIC50 | MIC90 | MIC range | |
| Oxacillin | 66.2 | 0 | 4 | 4 | 0.25–4 | 11.1 | 0 | 0.5 | 2 | 0.25–4 | 44.0 | 0 | 0.25 | 4 | 0.25–4 |
| Ciprofloxacin | 40.5 | 12.2 | 2 | 8 | 0.5–8 | 0 | 11.1 | 0.5 | 0.5 | 0.5–2 | 8.0 | 0 | 0.5 | 4 | 0.5–8 |
| Levofloxacin | 50.0 | 4.1 | 3 | 8 | 0.12–8 | 0 | 0 | 0.25 | 0.25 | 0.12–1 | 8.0 | 16.0 | 0.25 | 2 | 0.12–4 |
| Rifampicin | 8.1 | 0 | 0.5 | 1 | 0.5–32 | 0 | 0 | 0.5 | 0.5 | 0.5 | 8.0 | 4.0 | 0.5 | 2 | 0.25–4 |
| Gentamicin | 0 | 2.7 | 0.5 | 4 | 0.5–8 | 0 | 0 | 0.5 | 1 | 0.5–1 | 0 | 4.0 | 0.5 | 2 | 0.5–8 |
| Tetracycline | 16.2 | 4.1 | 2 | 16 | 1–16 | 11.1 | 0 | 1 | 2 | 1–16 | 0 | 0 | 1 | 1 | 1–2 |
| Clindamycin | 21.6 | 1.4 | 0.25 | 8 | 0.25–8 | 22.2 | 0 | 0.25 | 8 | 0.25–8 | 12.0 | 4.0 | 0.25 | 8 | 0.25–8 |
| Erythromycin | 51.4 | 2.7 | 8 | 8 | 0.25–8 | 44.4 | 0 | 0.25 | 8 | 0.5–8 | 44.0 | 8.0 | 8 | 8 | 0.25–8 |
| Linezolid | 0 | 0 | 1 | 2 | 0.25–4 | 0 | 0 | 2 | 2 | 1–4 | 0 | 0 | 2 | 2 | 0.25–4 |
| Vancomycin | 0 | 0 | 1 | 2 | 0.5–4 | 0 | 0 | 0.5 | 1 | 0.5–1 | 0 | 0 | 1 | 2 | 0.5–2 |
Comparison of clinical manifestations, treatment, and outcomes between Gram-positive and Gram-negative pathogens.
| Gram-positive cocci ( | Gram-negative bacilli ( | ||
|---|---|---|---|
| Clinical symptoms | |||
| Purulent exudate, | 57 (50.9) | 8 (40.0) | 0.369 |
| Device exposure, | 26 (23.2) | 10 (50.0) | 0.013∗ |
| Fever or chills, | 5 (4.5) | 5 (25.0) | 0.001∗ |
| Vegetation, | 6 (5.4) | 4 (20.0) | 0.023∗ |
| Antimicrobial therapy | |||
| Median duration (max, min), days | 13 (9–16) | 15.5 (10.5–18.75) | 0.174 |
| Adjustment based on culture results, | 19 (17.0) | 9 (45.0) | 0.005∗ |
| Inappropriate empirical therapy, | 52 (47.7) | 10 (50.0) | 0.850 |
| Outcomes | |||
| Poor wound healing, | 5 (4.5) | 2 (10.0) | 0.309 |
| Fever or chills, | 16 (14.3) | 4 (20.0) | 0.511 |
| Median length of stay (max, min), days | 15 (13–19) | 16.5 (14–22.5) | 0.199 |
| In-hospital death, | 0 | 0 | – |